4-[2-(5-ethylcyclooctyl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxopyrimidin-4-yl]-2-fluorobenzonitrile
C29H31F2N3O2 — CID 123276951
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-[2-(5-ethylcyclooctyl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxopyrimidin-4-yl]-2-fluorobenzonitrile
4-[2-(5-ethylcyclooctyl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxopyrimidin-4-yl]-2-fluorobenzonitrile (PubChem CID 123276951) has the molecular formula C29H31F2N3O2 and a molecular weight of 491.58 g/mol. Its IUPAC name is 4-[2-(5-ethylcyclooctyl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxopyrimidin-4-yl]-2-fluorobenzonitrile.
Molecular Properties
| Compound Name | 4-[2-(5-ethylcyclooctyl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxopyrimidin-4-yl]-2-fluorobenzonitrile |
|---|---|
| PubChem CID | 123276951 |
| Molecular Formula | C29H31F2N3O2 |
| Molecular Weight | 491.58 g/mol |
| Exact Mass | 491.24 |
| IUPAC Name | 4-[2-(5-ethylcyclooctyl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxopyrimidin-4-yl]-2-fluorobenzonitrile |
| SMILES | CCC1CCCC(c2nc(-c3ccc(C#N)c(F)c3)c(-c3ccc(OC)c(F)c3)c(=O)n2C)CCC1 |
| InChI | InChI=1S/C29H31F2N3O2/c1-4-18-7-5-9-19(10-6-8-18)28-33-27(21-11-12-22(17-32)23(30)16-21)26(29(35)34(28)2)20-13-14-25(36-3)24(31)15-20/h11-16,18-19H,4-10H2,1-3H3 |
| InChIKey | XFTFNHHOFSGEQE-UHFFFAOYSA-N |
| XLogP | 6.74 |
| TPSA | 67.91 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 36 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 491.58 |
| LogP ≤ 5 | 6.74 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 123276951 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.